NEW YORK, Dec. 21 (GenomeWeb News) - Iconix Pharmaceuticals has won a Phase I SBIR grant from the National Cancer Institute to develop new cell-based methods for testing drug candidates for liver toxicity, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.